Improving mitochondrial function to slow down ALS progression
Preserving Mitochondrial Function for Alleviating ALS Progression
This study is looking at how fixing problems with tiny energy factories in our cells, called mitochondria, might help people with ALS feel better and live longer, while also exploring how a healthy gut and diet can make a difference in their condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Arlington NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project ID | NIH-10609946 on NIH RePORTER |
What this research studies
This research investigates the role of mitochondrial dysfunction in the progression of amyotrophic lateral sclerosis (ALS), a severe neuromuscular disease. By using ALS mouse models, the study explores how restoring mitochondrial function in skeletal muscle can alleviate symptoms and potentially extend life. The researchers have discovered that gut health, particularly the presence of beneficial bacteria, plays a significant role in ALS progression, and dietary interventions may improve outcomes. Patients may benefit from insights into how dietary changes can impact their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with amyotrophic lateral sclerosis, particularly those experiencing early symptoms.
Not a fit: Patients with advanced stages of ALS or those with other unrelated neuromuscular diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new dietary strategies that help slow the progression of ALS and improve quality of life for patients.
How similar studies have performed: Previous research has shown promising results in using dietary interventions to improve gut health and potentially impact ALS progression, indicating that this approach may be viable.
Where this research is happening
Arlington, United States
- University of Texas Arlington — Arlington, United States (Active)
Researchers
- Principal investigator: Zhou, Jingsong — University of Texas Arlington
- Study coordinator: Zhou, Jingsong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.